Drug Profile
Dalotuzumab - Merck & Co
Alternative Names: Anti-IGF-1 receptor monoclonal antibody - Pierre Fabre; Anti-IGF-1R monoclonal antibody - Pierre Fabre; F 50 035; h7C10; MK-0646Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Developer M. D. Anderson Cancer Center; Merck & Co
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Insulin-like growth factor-I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Multiple myeloma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 22 Apr 2021 Discontinued - Phase-I for Breast cancer (First-line therapy) in USA, European Union, South Korea, Israel, Brazil (IV) before April 2021 (Merck & Co's pipeline, April 2021) (Pieree Fabre's pipeline, April 2021)
- 22 Apr 2021 Discontinued - Phase-II for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, Denmark, France, Germany, Italy, Spain, Sweden, United Kingdom, Canada, Colombia, Israel, South Korea, Peru, Taiwan, USA, Brazil, Japan, Czech Republic, Portugal (IV) before April 2021 (Merck & Co's pipeline, April 2021) (Pieree Fabre's pipeline, April 2021)
- 22 Apr 2021 Discontinued - Phase-II for Colorectal cancer (Combination therapy, Metastatic disease) in Germany, Italy, South Korea, Peru, Taiwan, USA (IV) before April 2021 (Merck & Co's pipeline, April 2021) (Pieree Fabre's pipeline, April 2021)